Prot #MK-7655A-014-01: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects with Hospital

Project: Research project

Project Details

StatusFinished
Effective start/end date1/6/16 → 1/6/22

Funding

  • Merck Sharp & Dohme Corporation (Prot #MK-7655A-014-01)